^
    Back
    Association details:
    Biomarker:LRP1B mutation + TMB-H
    Cancer:Bladder Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2021
    Title:

    356 - Association of LRP1B mutation with tumor mutation burden and survival in bladder cancer patients treated with immune checkpoint inhibitors

    Published date:
    03/10/2021
    Excerpt:
    The association between LRP1B mutation with TMB was analyzed in bladder cancer patients from the public immunotherapy-treated cohort...LRP1B mutation is associated with higher TMB in both public cohort(p=0.028)...Survival analysis in the public cohort demonstrated that LRP1B mutation resulted in significantly longer OS ( 16.8 vs 8.08 months; HR, 0.16; p=0.043) and a increasing trend on PFS without significant difference...